Respiratory Virus News and Research

RSS

Are pre-existing Vitamin D deficiencies linked to COVID-19 severity and mortality?

Even as the COVID-19 pandemic continues to spread and new variants of SARS-CoV-2 emerge, much remains to be known about why severity varies so unpredictably between individuals. A new study, released as a preprint on the medRxiv* server, elucidates the relationship between Vitamin D and COVID-19 severity.

10 Jun 2021

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

In a recently published article in the journal Frontiers in Immunology, scientists have reviewed the existing literature on antiviral and anti-inflammatory efficacy of resveratrol-based inhaled formulations in preventing SARS-CoV-2 infection and reducing COVID-19 severity.

9 Jun 2021

People who received Pfizer-Biontech vaccine have lower antibody levels targeting the delta variant

Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Thursday) as a Research letter in The Lancet.

4 Jun 2021

Plant-based oil blend shows virucidal activity against SARS-CoV-2 and influenza viruses in vitro

A new preprint research paper posted to the bioRxiv* server offers a potential candidate for disinfecting the respiratory tract and mouth during and after exposure to the virus, in the form of proprietary herbal oil named Viruxal.

3 Jun 2021

New survey highlights key role of ECT for treating severe depression, other conditions

When the COVID-19 pandemic arrived in North America in March 2020, health care facilities stopped providing all but "essential" care, to reduce infection risks and preserve protective gear known as PPE.

3 Jun 2021

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

A new study has been published in the Journal of Biomolecular Structure and Dynamics which focuses on the evaluation of E, M, N, ORF10, ORF8, ORF3a, and M proteins using bioinformatics tools to develop a multi-epitope COVID-19 vaccine. The researchers utilized in-silico methods to incite humoral and cellular immune responses.

31 May 2021

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

A team of international scientists recently conducted a randomized clinical trial to assess the safety and efficacy profiles of a novel probiotic formulation in symptomatic coronavirus disease 2019 (COVID-19) patients. The findings indicate that the probiotic formulation is highly effective in reducing symptom severity in COVID-19 patients without causing any adverse events.

25 May 2021

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

Researchers in the UK have demonstrated the efficacy of the Pfizer-BioNTech and AstraZeneca vaccines against severe acute respiratory virus coronavirus 2 (SARS-CoV-2) at preventing death among older individuals with coronavirus disease 2019 (COVID-19).

20 May 2021

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

COVID-19, the coronavirus disease of 2019, is one of the worst pandemics in human history. It emerged in December 2019 and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nearly 164 million SARS-CoV-2 infections and 3.4 million deaths have been reported globally since the beginning of the pandemic, which is still raging in many countries.

18 May 2021

COVID-19 public health interventions reduced other respiratory infections

Wearing masks and quarantining while sick has helped mitigate the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An indirect benefit of these efforts appears to be a decrease in flu cases and other respiratory infections. New research led by Lisa G. Winston of the University of California, San Francisco, confirmed COVID-19 public health interventions helped decrease the number of airborne viruses.

18 May 2021

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

Scientists at the University of Zurich have modified a common respiratory virus, called adenovirus, to act like a Trojan horse to deliver genes for cancer therapeutics directly into tumor cells. Unlike chemotherapy or radiotherapy, this approach does no harm to normal healthy cells.

18 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

Novel chip-based antigen test can provide ultrasensitive detection of SARS-CoV-2, influenza A

Researchers at UC Santa Cruz have developed a novel chip-based antigen test that can provide ultrasensitive detection of SARS-CoV-2 and influenza A, the viruses that cause COVID-19 and flu, respectively.

12 May 2021

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

Researchers in the United States and Austria have demonstrated the potential of a modified influenza virus as a vaccine to protect against viral respiratory pathogens, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

2 May 2021

COVID-19 survivors have increased risk of death for at least six months

As the COVID-19 pandemic has progressed, it has become clear that many survivors -; even those who had mild cases -; continue to manage a variety of health problems long after the initial infection should have resolved.

23 Apr 2021

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.

19 Apr 2021

Measurable antibody response to mRNA COVID-19 vaccine in elderly care home residents

A new preprint research paper posted to the medRxiv* server explores the antibody response to COVID-19 vaccines in elderly residents of nursing homes in the USA. As of March 2021, there have been over 1.4 million infections from SARS-CoV-2 and over 175,000 deaths related to the pandemic among nursing home residents in the country.

13 Apr 2021

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

A new preprint, recently released on the bioRxiv* server, explores the impact of a single mutation, the P681H mutation, on the transmissibility of the virus.

12 Apr 2021

Scientists identify nine potential new COVID-19 treatments

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that are already approved by the Food and Drug Administration (FDA) for treating other diseases.

2 Apr 2021

Changing upper respiratory microbiome in children related to SARS-CoV-2 susceptibility

Researchers tested the nasopharyngeal microbiome of children up to 21 years old and found the microbiome changes with age. Specific bacteria, whose abundance also changes with age, are associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection susceptibility and severity.

25 Mar 2021

Respiratory Virus News and Research

Are pre-existing Vitamin D deficiencies linked to COVID-19 severity and mortality?

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

People who received Pfizer-Biontech vaccine have lower antibody levels targeting the delta variant

Plant-based oil blend shows virucidal activity against SARS-CoV-2 and influenza viruses in vitro

New survey highlights key role of ECT for treating severe depression, other conditions

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

COVID-19 public health interventions reduced other respiratory infections

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

Nanotechnology and COVID-19 diagnosis and treatment

Novel chip-based antigen test can provide ultrasensitive detection of SARS-CoV-2, influenza A

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

COVID-19 survivors have increased risk of death for at least six months

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

Measurable antibody response to mRNA COVID-19 vaccine in elderly care home residents

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

Scientists identify nine potential new COVID-19 treatments

Changing upper respiratory microbiome in children related to SARS-CoV-2 susceptibility

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News